Perspective Therapeutics (NYSEAMERICAN:CATX) Director Buys $19,950.00 in Stock

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX – Get Free Report) Director Lori Woods bought 23,750 shares of the business’s stock in a transaction on Thursday, November 12th. The shares were acquired at an average cost of $0.84 per share, for a total transaction of $19,950.00. Following the transaction, the director directly owned 28,557 shares in the company, valued at approximately $23,987.88. This trade represents a 494.07% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website.

Perspective Therapeutics Trading Down 9.3%

NYSEAMERICAN:CATX opened at $0.78 on Thursday. The firm has a 50-day simple moving average of $1.98 and a 200-day simple moving average of $3.40. Perspective Therapeutics, Inc. has a one year low of $0.78 and a one year high of $6.16. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.18 and a current ratio of 5.18.

Perspective Therapeutics (NYSEAMERICAN:CATX – Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). Perspective Therapeutics had a negative net margin of 55,866.82% and a negative return on equity of 42.25%. The business had revenue of $0.02 million for the quarter, compared to analysts’ expectations of $0.06 million. On average, equities research analysts forecast that Perspective Therapeutics, Inc. will post -1.01 earnings per share for the current year.

Analyst Upgrades and Downgrades

CATX has been the subject of several analyst reports. Piper Sandler decreased their price target on shares of Perspective Therapeutics from $16.00 to $14.00 and set an “overweight” rating for the company in a research report on Tuesday, August 11th. William Blair initiated coverage on shares of Perspective Therapeutics in a research report on Friday, September 18th. They issued an “outperform” rating on the stock. Wedbush reiterated an “outperform” rating and set a $7.00 price objective (down from $9.00) on shares of Perspective Therapeutics in a research note on Tuesday, November 10th. BMO Capital Markets reiterated an “outperform” rating on shares of Perspective Therapeutics in a research note on Friday, October 30th. Finally, Bank of America decreased their target price on shares of Perspective Therapeutics from $6.00 to $5.00 and set a “neutral” rating for the company in a research report on Friday, August 14th. Nine investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.10.

Get Our Latest Report on Perspective Therapeutics

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP raised its stake in Perspective Therapeutics by 391.6% in the first quarter. Dimensional Fund Advisors LP now owns 450,097 shares of the company’s stock valued at $1,877,000 after buying an additional 358,540 shares during the last quarter. Avidity Partners Management LP boosted its holdings in Perspective Therapeutics by 88.4% in the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock worth $25,228,000 after acquiring an additional 2,839,266 shares in the last quarter. Seven Fleet Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $1,581,000. Yu Fan purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $4,401,000. Finally, Commodore Capital LP purchased a new stake in shares of Perspective Therapeutics during the first quarter worth about $26,424,000. 54.66% of the stock is currently owned by hedge funds and other institutional investors.

About Perspective Therapeutics

(Get Free Report)

Perspective Therapeutics is a clinical-stage radiopharmaceutical company developing targeted alpha-particle therapies for cancer. Its approach combines radioactive lead-212 with molecules designed to bind to specific targets on tumor cells, with the goal of delivering radiation directly to tumors while limiting exposure to surrounding tissue. The company’s investigational pipeline includes therapies aimed at cancers such as neuroendocrine tumors and metastatic melanoma. Its programs include compounds designed to target somatostatin receptors and melanocortin 1 receptors.

Recommended Stories

Insider Buying and Selling by Quarter for Perspective Therapeutics (NYSEAMERICAN:CATX)

Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.